The Entry of Zika Virus into the Cells and Its Implication for Antiviral Therapy., PMID:40512550
Exploring T-cell bispecific antibodies in gynecologic malignancy., PMID:40502816
IL-18 inhibition enlarges lesions, necrotic cores and thickens fibrous caps in Jak2 V617F clonal hematopoiesis-driven atherosclerosis., PMID:40501724
Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody-drug conjugate., PMID:40491605
Aptamers as therapeutic targets: prospects and progress in the treatment of cancers., PMID:40479828
BAP1-mediated ubiquitination inhibition and CAS6/AXL signaling activation in bladder cancer progression., PMID:40330545
Nanoparticle-Mediated Cosilencing of Drug Resistance and Compensatory Genes Enhances Lung Cancer Therapy., PMID:40239042
Development of Antibody-Drug Conjugates for Malignancies of the Uterine Corpus: A Review., PMID:40072062
Vitamin K supports TGF-β1 depended in vitro human Langerhans cell differentiation and function via Axl., PMID:40040711
Synergistic Inhibition of Drug Resistant KRAS Mutant Non-Small Cell Lung Cancer by Co-Targeting AXL and SRC., PMID:39941857
AXL signaling in cancer: from molecular insights to targeted therapies., PMID:39924521
Efficacy of Second-line Nivolumab Versus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma With Bone Metastases., PMID:39890197
Lineage-dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and independent immunotherapeutic targets., PMID:39825754
Changes in AXL and/or MITF melanoma subpopulations in patients receiving immunotherapy., PMID:39697983
Emerging AXL Inhibitors in Oncology: Chemical and Biological Advances in Targeted Cancer Therapy., PMID:39679460
Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab., PMID:39632711
NPS-1034 Exerts Therapeutic Efficacy in Renal Cell Carcinoma Through Multiple Targets of MET, AXL, and TNFRSF1A Signaling in a Metastatic Model., PMID:39451232
AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies., PMID:39367387
DSP-0509, a TLR7 agonist, exerted synergistic anti-tumor immunity combined with various immune therapies through modulating diverse immune cells in cancer microenvironment., PMID:39346737
SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer., PMID:39235596
A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib., PMID:39216477
Immuno-targeting the ectopic phosphorylation sites of PDGFRA generated by MAN2A1-FER fusion in HCC., PMID:39082961
Antibody-Drug Conjugates in the Pipeline for Treatment of Melanoma: Target and Pharmacokinetic Considerations., PMID:38951479
Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial., PMID:38942995
Serum AXL is a potential molecular marker for predicting COVID-19 progression., PMID:38799467
A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer., PMID:38795600
Anti-PD-L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy-refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study., PMID:38781433
AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid Leukemia., PMID:38773967
Role of TAM Receptors in Antimalarial Humoral Immune Response., PMID:38668253
The Vitamin K-Dependent Anticoagulant Factor, Protein S, Regulates Vascular Permeability., PMID:38666935
Pan-cancer Genomic Analysis of AXL Mutations Reveals a Novel, Recurrent, Functionally Activating AXL W451C Alteration Specific to Myxofibrosarcoma., PMID:38369783
Impact of sunitinib resistance on clear cell renal cell carcinoma therapeutic sensitivity in vitro., PMID:38263737
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma., PMID:38105142
Targeting GAS6/AXL signaling improves the response to immunotherapy by restoring the anti-immunogenic tumor microenvironment in gastric cancer., PMID:37952835
Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/pertuzumab for HER2-positive breast cancer., PMID:37924622
Resistance of Lung Cancer to EGFR-Specific Kinase Inhibitors: Activation of Bypass Pathways and Endogenous Mutators., PMID:37894376
Correction: Receptor tyrosine kinases Tyro3, Axl, and Mertk differentially contribute to antibody-induced arthritis., PMID:37653485
L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab., PMID:37557179
Anti-PD-L1 antibodies promote cellular proliferation by activating the PD-L1-AXL signal relay in liver cancer cells., PMID:37553470
Targeted degradation of MERTK and other TAM receptor paralogs by heterobifunctional targeted protein degraders., PMID:37545504
Receptor tyrosine kinases Tyro3, Axl, and Mertk differentially contribute to antibody-induced arthritis., PMID:37537628
Altered expression of AXL receptor tyrosine kinase in gastrointestinal cancers: a promising therapeutic target., PMID:37469409
Verifying AXL and putative proteins as SARS-CoV-2 receptors by DnaE intein-based rapid cell-cell fusion assay., PMID:37461287
Coreceptor AXL Facilitates African Swine Fever Virus Entry via Apoptotic Mimicry., PMID:37382521
Arising Novel Agents in Lung Cancer: Are Bispecifics and ADCs the New Paradigm?, PMID:37370772
Central role of lung macrophages in SARS-CoV-2 physiopathology: a cross-model single-cell RNA-seq perspective., PMID:37350967
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer., PMID:37143061
Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial., PMID:37041632
Therapeutic Landscape of AXL Receptor Kinase in Triple-Negative Breast Cancer., PMID:37028809
A procedure for producing an anti-AXL nanobody in E. coli., PMID:37023993
For research use only. Not for human or drug use.
